News

Public · Published

Palantir Has to Top Itself Again for the Stock to Keep Going — Barrons.com

Palantir's sales growth accelerated each quarter from the third quarter of 2023 through the second quarter this year, when sales rose 93% and its operating margin was 47%. Ahead of Monday's third-quarter earnings report, analysts expect 84% sales growth, a 46% operating margin, and 133% growth in U.S. commercial revenue.

Published:

Updated:

What happened

Palantir’s sales growth accelerated each quarter from the third quarter of 2023 through the second quarter this year, when sales rose 93% and its operating margin was 47%. Ahead of Monday’s third-quarter earnings report, analysts expect 84% sales growth, a 46% operating margin, and 133% growth in U.S. commercial revenue.

Confirmed

Global impact / market context

The report will show whether Palantir can keep turning demand for its data and artificial-intelligence software into fast sales growth and strong profit per sale. If growth and operating margin ease as analysts expect, investors may reassess how much future expansion the stock price assumes.

Analyst inference

The article contrasts government sales, expected to grow 76%, with U.S. commercial sales, the larger recent growth driver, for which analysts project 133% growth versus 150% last quarter. That points to commercial customer demand as a key measure of whether rapid expansion continues.

Confirmed

What to watch

  1. Compare reported third-quarter sales growth with analysts’ 84% forecast; a larger slowdown could weaken expectations for future revenue and put pressure on investors’ view of the stock. Analyst inference
  2. Check the reported operating margin against the expected 46%; this measures operating profit as a share of sales and can reveal whether growth is becoming less profitable. Confirmed
  3. Watch U.S. commercial revenue growth against the projected 133% and government sales growth against 76%; weaker commercial demand would challenge the recent main source of expansion. Confirmed

Evidence

  • Original source link unavailable